Callio Therapeutics
Callio Therapeutics is a biotechnology company focused on developing multi-payload antibody-drug conjugate technology to enhance therapeutic outcomes for cancer patients. By overcoming the limitations of existing single-payload therapies, Callio aims to maximize the therapeutic benefits of its innovative programs.
Leadership & Board
Key Executives
- CEO & Co-Founder
- Piers Ingram
- CSO & Co-Founder
- Jerome Boyd-Kirkup
- CMO
- Naomi Hunder
- CBO
- Angele Maki
- Current Number of Employees
- 24
- Current LinkedIn Followers
- 4,633
Latest Estimated Valuation
- Estimated Valuation
- ―
- Total Amount Raised
- $187M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $187M
- Latest Funding Round
- Series A
- Post-Money Valuation
- ―
Company Momentum Positive
Callio Therapeutics LinkedIn following is increasing, signaling rising market interest, while its workforce is growing, indicating business expansion.
Employee Trend
Callio Therapeutics had 24 employees as of October 12, 2026. The number of employees increased by 1 (4.35%) week-over-week.
Social Trend
Callio Therapeutics had 4,633 followers as of October 12, 2026. The number of followers increased by 26 (0.56%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Mar 03, 2025 | Series A | $187.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Omega Funds | Series A |
| Frazier Life Sciences | Series A |
| Jeito Capital | Series A |
| Novo Holdings A/S | Series A |
| ClavystBio | Series A |
| Platanus | Series A |
| Norwest | Series A |
| Pureos Bioventures | Series A |
Similar Companies
A snapshot of private companies similar to Callio Therapeutics, helping you discover and navigate related company profiles.
